Publications

Abstract: Phase 1a dose-escalation study of RS-0139: A novel tumor-targeted nanomedicine for advanced solid tumors

ASCO 2025 Congress
^{30 May – 3 June 2025, Chicago}

Poster: RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models

ESMO TAT 2023 Congress
^{6-8 March 2023, Paris}

Poster: Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer

ESMO 2022 Congress
^{9-13 September 2022, Paris}